×

Business / Stock Market

BSX : Trial Of TheraSphere Y-90 Glass Microspheres On Metastatic Colorectal Cancer Meets Main Goal

Published Sep 20 2021 at 12:16 PM GMT

Business Insider

Business Insider @businessinsider.com

Add to Collections
Report Post

Continue reading at businessinsider.com

Key
Points

(BSX) said that late-breaking data demonstrated improved progression-free survival in patients with metastatic colorectal cancer after treatment with boston scientific therasphere Y-90 Glass Microspheres.
The company noted that the EPOCH clinical trial of the TheraSphere Y-90 Glass Microspheres (TheraSphere.

Credit

Tags

Continue reading at businessinsider.com

Posted in Business, Stock Market

Stats

Published Sep 20, 2021 12:16 PM GMT